Patients diagnosed with coronary heart disease (CHD) have a lower cognitive performance, a new study suggests.

Research published in the European Heart Journal found that an individual's mental processes, such as reasoning, vocabulary and verbal fluency, can be impaired by the presence of heart disease.

The study found that among both men and women a history of CHD could be linked to lower scores for reasoning, vocabulary and their global cognitive status (MMSE), when compared to people who had no CHD history.

Lead researcher Dr Archana Singh-Manoux commented: "It is important to elucidate the link between these two diseases.

"Our core hypothesis is that the identification of the risk factors for dementia needs to focus on the determinants of cognitive ageing in midlife and early old age."

He explained: "Our results on the link between CHD and cognition underline the importance of these preventive measures by highlighting the impact of these risk factors not only on CHD but also on people's cognitive functioning."

As the prevalence of dementia rises with age, more than a third of people older than 80 are likely to have the condition, while CHD remains the leading cause of death in many western countries.

Register now to access our FREE educational libraryLogin and visit the Alzheimer's Disease Knowledge Centre

• Study highlights lack of sleep and exercise as cancer risk 18/11/08
• Doctors warned over pre-eclampsia risk in pregnant women 05/11/08
• Yoghurt found to reduce cancer risk 17/10/08
• Gender link explored in CHD research 14/10/08
• Additional testing may improve breast cancer risk assessment 29/07/08

• TRITACE Tablets - 24.72%
  ... more who have one or more of the following clinical findings: hypertension (systolic blood pressure> 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease ...
  
  
• TRITACE Titration Pack - 24.36%
  ... who have one or more of the following clinical findings: hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease. Oral ...
  
  
• BETAFERON - 23.54%
  ... of clinical relapses in ambulatory patients, who have had at least two attacks of neurological dysfunction in the preceding two years followed by complete or incomplete recovery. Secondary progressive multiple sclerosis - Slowing progression of disease and reduction in frequency of clinical relapses ...
  
  
• LOCOID Ointment - 22.5%
  The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided ...
  
  
• NAGLAZYME Solution for Infusion - 22.5%
  ... it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease. A key issue is to treat young patients aged <5 years suffering from a severe form of the disease, even though patients <5 ...
  
  
• ELAPRASE Solution for Infusion - 22.5%
  Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials ...